Ankylosing spondylitis: a beta2m-deposition disease?

Barbara Uchanska-Ziegler1, Andreas Ziegler

  • 1Institut für Immungenetik, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Spandauer Damm 130, 14050 Berlin, Germany. barbara.uchanska-ziegler@charite.de

Trends in Immunology
|January 28, 2003
PubMed

Insights

The study proposes that beta(2)-microglobulin release from HLA-B27 molecules triggers inflammation, explaining the link between HLA-B27 and ankylosing spondylitis. This process leads to joint damage in spondyloarthropathy.

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Molecular Biology

Background:

  • The human leukocyte antigen B27 (HLA-B27) is strongly associated with ankylosing spondylitis.
  • The exact mechanism linking HLA-B27 to the disease remains incompletely understood.

Purpose of the Study:

  • To elucidate the molecular mechanism underlying the association between HLA-B27 and ankylosing spondylitis.

Main Methods:

  • The study suggests a hypothesis involving the release of beta(2)-microglobulin (beta(2)m) from HLA-B27 molecules.
  • This release is proposed to occur from a subpopulation of cell surface-expressed HLA-B27.

Main Results:

  • The proposed mechanism involves beta(2)m deposition within synovial tissues.
  • This deposition is hypothesized to initiate an inflammatory cascade.

Conclusions:

  • The release of beta(2)m from HLA-B27 molecules is suggested as a key factor in the pathogenesis of ankylosing spondylitis.
  • This process culminates in destructive spondyloarthropathy.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Degenerative Disc Disease ll: Pathophysiology01:23

Degenerative Disc Disease ll: Pathophysiology

The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...